CERo Therapeutics Accounts Payable Over Time
| CEROW Stock | 0.02 0.0002 1.00% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out CERo Therapeutics Performance and CERo Therapeutics Correlation. CERo |
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CERo Therapeutics. If investors know CERo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CERo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of CERo Therapeutics is measured differently than its book value, which is the value of CERo that is recorded on the company's balance sheet. Investors also form their own opinion of CERo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CERo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CERo Therapeutics' market value can be influenced by many factors that don't directly affect CERo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CERo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if CERo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CERo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Accounts Payable Analysis
Compare CERo Therapeutics and related stocks such as Vivani Medical, Verve Therapeutics, and Bright Minds Biosciences Accounts Payable Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VANI | 731.4 K | 731.4 K | 731.4 K | 314.3 K | 513.1 K | 710 K | 1.2 M | 752 K | 1.3 M | 1.1 M | 223 K | 281 K | 1.2 M | 542 K | 806.5 K |
| VERV | 2.4 M | 2.4 M | 2.4 M | 2.4 M | 2.4 M | 2.4 M | 2.4 M | 2.4 M | 2.4 M | 2.4 M | 36 K | 7.1 M | 2.4 M | 6.6 M | 4.1 M |
| DRUG | 36.7 K | 36.7 K | 36.7 K | 36.7 K | 36.7 K | 36.7 K | 36.7 K | 36.7 K | 36.7 K | 138.4 K | 596.6 K | 1.2 M | 182.3 K | 209.7 K | 199.2 K |
| DRTS | 893 K | 893 K | 893 K | 893 K | 893 K | 893 K | 893 K | 893 K | 893 K | 893 K | 964 K | 1.2 M | 1.4 M | 2.6 M | 1.6 M |
| SRZNW | 972 K | 972 K | 972 K | 972 K | 972 K | 972 K | 972 K | 972 K | 972 K | 972 K | 1.8 M | 2.7 M | 658 K | 525 K | 498.8 K |
| VNDA | 718.6 K | 996 K | 287 K | 661 K | 835 K | 15.8 M | 16.2 M | 20.3 M | 21.6 M | 5.9 M | 1 M | 925 K | 12.7 M | 7.1 M | 6.4 M |
| VRCA | 103 K | 103 K | 103 K | 103 K | 103 K | 103 K | 103 K | 167 K | 960 K | 1.2 M | 348 K | 845 K | 507 K | 2.5 M | 2.6 M |
| VRNA | 20.6 K | 138.2 K | 322.1 K | 543.8 K | 570.6 K | 1.9 M | 887.1 K | 1.6 M | 3.6 M | 1.9 M | 178 K | 10 M | 2.9 M | 3.5 M | 3.7 M |
| VRPX | 6.6 K | 6.6 K | 6.6 K | 6.6 K | 6.6 K | 6.6 K | 6.6 K | 6.6 K | 6.6 K | 3.5 | 22.1 K | 19.8 K | 37.6 K | 18.46 | 17.54 |
CERo Therapeutics and related stocks such as Vivani Medical, Verve Therapeutics, and Bright Minds Biosciences Accounts Payable description
An accounting item on the balance sheet that represents CERo Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of CERo Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.My Equities
My Current Equities and Potential Positions
| CERo Therapeutics Holdings | CEROW |
Specialization | Healthcare, Biotechnology |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
null 0.0198
Additional Tools for CERo Stock Analysis
When running CERo Therapeutics' price analysis, check to measure CERo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CERo Therapeutics is operating at the current time. Most of CERo Therapeutics' value examination focuses on studying past and present price action to predict the probability of CERo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CERo Therapeutics' price. Additionally, you may evaluate how the addition of CERo Therapeutics to your portfolios can decrease your overall portfolio volatility.